Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy

Graphical abstract

Saved in:
Bibliographic Details
Published inCancer treatment reviews Vol. 45; pp. 7 - 18
Main Authors Eigentler, Thomas K, Hassel, Jessica C, Berking, Carola, Aberle, Jens, Bachmann, Oliver, Grünwald, Viktor, Kähler, Katharina C, Loquai, Carmen, Reinmuth, Niels, Steins, Martin, Zimmer, Lisa, Sendl, Anna, Gutzmer, Ralf
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 01.04.2016
Subjects
Adverse drug reaction
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal - pharmacology
Antibodies, Monoclonal, Humanized - immunology
Antibodies, Monoclonal, Humanized - pharmacology
Antineoplastic Agents - immunology
Antineoplastic Agents - pharmacology
B7-H1 Antigen - antagonists & inhibitors
Disease Management
Drug-Related Side Effects and Adverse Reactions - drug therapy
Drug-Related Side Effects and Adverse Reactions - etiology
Drug-Related Side Effects and Adverse Reactions - immunology
Early Diagnosis
Hematology, Oncology and Palliative Medicine
Humans
Immune-related adverse events
Immunosuppressive Agents - therapeutic use
Immunotherapy
Monitoring, Immunologic
Neoplasms - drug therapy
Nivolumab
PD-1
Pembrolizumab
Programmed Cell Death 1 Receptor - immunology
Pembrolizumab
Immune-related adverse events
Adverse drug reaction
PD-1
Immunotherapy
Nivolumab
Online AccessGet full text

Cover

More Information
Summary:Graphical abstract
ISSN:0305-7372
1532-1967
DOI:10.1016/j.ctrv.2016.02.003